Gynecologic and Reproductive Health Concerns of Adolescents Using Selected Psychotropic Medications

详细信息    查看全文

• 作者：Hina J. Talib ; MD ; ^{htalib@montefiore.org} ; Elizabeth M. Alderman ; MD
• 刊名：Journal of Pediatric and Adolescent Gynecology
• 出版年：2013
• 出版时间：February, 2013
• 年：2013
• 卷：26
• 期：1
• 页码：7-15
• 全文大小：138 K

文摘

Psychiatric disorders are common in adolescent girls and may require chronic therapies with psychotropic medications. Antipsychotic medications and mood stabilizers have been increasingly prescribed to and widely used by adolescents for a variety of both ¡°on¡± an ¡°off¡± label indications. Studies on the safety and monitoring of these medications in adolescent girls have shown important potential for gynecologic and reproductive adverse effects. The objective of this article is to review the mechanisms for and management of menstrual disorders mediated by hyperprolactinemia associated with antipsychotic medications, hypothyroidism associated with lithium and quetiapine, and the independent association of polycystic ovary syndrome (PCOS) in girls using valproic acid. Beyond their susceptibility to these disruptions in the menstrual cycle, adolescent girls with psychiatric illness also have increased sexual risk behaviors. These behaviors makes it all the more important to review teratogenicity and clinically relevant contraceptive drug interactions in adolescent girls using these psychotropic medications.